Welcome to our dedicated page for Calidi Biotherapeutics news (Ticker: CLDI), a resource for investors and traders seeking the latest updates and insights on Calidi Biotherapeutics stock.
Calidi Biotherapeutics, Inc. (NYSE American: CLDI) is a clinical-stage immuno-oncology company developing systemically delivered, targeted genetic medicines based on its proprietary RedTail platform. This news page aggregates company-issued updates and related coverage so readers can follow how Calidi advances its oncolytic virus-based therapies and corporate strategy over time.
Calidi’s announcements frequently highlight progress with CLD-401, the first lead candidate from the RedTail platform. News items include preclinical data presented at scientific meetings such as the Society for Immunotherapy of Cancer (SITC) Annual Meeting, where the company has reported that its engineered enveloped oncolytic virus can avoid immune clearance after systemic administration, home to metastatic tumor sites, and express IL-15 superagonist and other genetic medicines within the tumor microenvironment.
Investors can also find updates on Calidi’s broader activities, including the formation of a Scientific Advisory Board, participation in investor conferences, and capital markets events such as underwritten public offerings. Press releases describe how the company is working with partners, such as a viral vector CDMO, to provide analytical development, process development, and GMP manufacturing support for CLD-401 as it moves through IND-enabling studies.
By reviewing the CLDI news feed, readers can track scientific milestones, financing developments, strategic collaborations, and investor communications related to Calidi’s efforts to develop RedTail-based virotherapies and protected intratumoral programs. This page is a useful reference for following the company’s disclosed progress in immuno-oncology and genetic medicine research.
Calidi Biotherapeutics, Inc. (NYSE American: CLDI), a clinical-stage biotechnology company, has announced that NYSE Regulation staff has decided to initiate delisting proceedings for the company's warrants (ticker symbol CLDI WS) from the NYSE American. The warrants, each exercisable for 1/10th of a common stock share at $115.00 per whole share, will be suspended from trading immediately.
The delisting decision is based on Section 1001 of the NYSE American Company Guide, citing the warrants' low trading price as unsuitable for listing. Calidi's common stock (CLDI) will continue to trade on the NYSE American. The company has the right to appeal this decision to the Listings Qualifications Panel. Upon completion of all procedures, including any potential appeal, the NYSE American will apply to the SEC for the official delisting of Calidi's warrants.
RedChip Companies will air interviews with Calidi Biotherapeutics (NYSE American:CLDI) and Gorilla Technology Group (Nasdaq:GRRR) on the RedChip Small Stocks, Big Money™ show on Bloomberg TV on October 19 at 7 p.m. ET. The show reaches an estimated 73 million homes across the U.S.
Calidi Biotherapeutics is pioneering oncolytic virotherapy (OV) for cancer treatment. Their approach uses engineered viruses to target cancer cells and stimulate immune response. Calidi's cell-based technologies protect OVs from immune system elimination, potentially increasing efficacy.
Gorilla Technology, with 22 years of experience and 29 global patents, specializes in digital transformation solutions. Their technologies include edge AI, big data analytics, and IoT security, serving sectors like government and manufacturing. Gorilla has buy ratings from three analysts with a mean price target of $29.50.
Calidi Biotherapeutics (NYSE American: CLDI) announced FDA clearance of Northwestern University's IND application for CLD-101, a novel stem-cell based platform delivering oncolytic viruses to tumors. A Phase 1b/2 clinical trial for newly diagnosed high-grade glioma is expected to start in late 2024 at Northwestern University. The trial will evaluate safety and feasibility of multiple CLD-101 doses in addition to standard treatments.
A previous Phase 1 study at Northwestern showed promising results, with median progression-free survival of 9.05 months and overall survival of 18.4 months. CLD-101 is also being evaluated in a Phase 1 trial for recurrent high-grade glioma at City of Hope, with interim data expected in the first half of 2025. City of Hope received a $5.3 million grant from CIRM to support CLD-101 studies in ovarian cancer.
Calidi Biotherapeutics Inc. (NYSEAM: CLDI) reported its Q2 2024 financial results and recent business highlights. Key developments include:
1. Launched Nova Cell subsidiary with a $2 million investment from Dr. Ronald Rigor to advance AAA stem cell programs.
2. Strengthened team with appointments of Dr. George E. Peoples to the Board of Directors and Dr. Mark Gilbert to the Medical Advisory Board.
3. Received a new U.S. patent for SuperNova technology, enhancing the CLD-201 program.
4. Reported a net loss of $5.8 million ($1.40 per share) for Q2 2024, compared to $12.5 million ($14.24 per share) in Q2 2023.
5. R&D expenses were $2.2 million, down from $3.2 million in Q2 2023.
6. Cash position of $0.8 million as of June 30, 2024.
RedChip Companies will air interviews with GreenPower Motor Company Inc. (Nasdaq:GP) and Calidi Biotherapeutics, Inc. on Bloomberg TV on August 3, 2024, at 7 p.m. ET. Fraser Atkinson, CEO of GreenPower, will provide a corporate update on the show. GreenPower is a leading manufacturer of all-electric, zero-emission medium and heavy-duty vehicles for various sectors including cargo, delivery, shuttle, transit, and school buses.
The company has delivered over 700 vehicles to date and maintains a significant order book. GreenPower's competitive positioning, sales growth, and market dynamics highlight its potential for sustained growth in the EV industry. The interview will be accessible online through a provided link.
Calidi Biotherapeutics (NYSE American: CLDI) has launched a new subsidiary, Nova Cell, Inc., and secured a $3 million investment from Dr. Ronald Rigor. The investment includes $2 million for Nova Cell and $1 million for Calidi's oncology pipeline. Nova Cell will focus on advancing Calidi's Adult Adipose Allogeneic (AAA) stem cell programs for regenerative medicine applications.
Dr. Rigor, a Board-Certified Dermatologist and Stem Cell Therapy expert, joins Calidi's Scientific and Medical Advisory Board. He receives exclusive rights to use AAA stem cells and Calidi's CLD-201 product in the Philippines. Nova Cell aims to tap into the global stem cell therapy market, projected to reach $31.4 billion by 2030. The company plans to begin generating revenue by supplying AAA stem cells to Dr. Rigor's patients in 2025.
Calidi Biotherapeutics (NYSE American: CLDI) has been granted U.S. Patent No. 12,036,278 for its SuperNova technology platform. This patent, titled 'Smallpox Vaccine for Cancer Treatment,' covers methods and compositions related to cancer immunotherapy, specifically combining smallpox vaccines with various stem cell types.
The patent strengthens Calidi's intellectual property portfolio and supports the advancement of its CLD-201 program into clinical trials. It broadens previously allowed claims to include 21 smallpox vaccine virus strains and 19 different stem cell types. The SuperNova platform aims to shield viral payloads from the immune system, enhancing delivery to tumor sites and improving the therapeutic efficacy of oncolytic viruses.
Calidi plans to submit an IND to initiate a first-in-human clinical trial of this off-the-shelf allogeneic therapy, focusing on patients with advanced solid tumors.
Calidi Biotherapeutics (NYSE American: CLDI) has appointed Dr. Mark Gilbert, scientist emeritus at the National Institutes of Health (NIH), to its Medical Advisory Board. Dr. Gilbert, former Chief of the Neuro-Oncology Branch at NIH, brings extensive experience in brain tumor research and clinical trials. His addition expands the board to eight members, joining other renowned oncologists and scientists.
Dr. Gilbert expressed interest in Calidi's SNV1 and NNV1 therapies, noting their potential to address rare cancers affecting about 25% of cancer patients. Calidi's CEO, Allan Camaisa, highlighted Dr. Gilbert's expertise in developing multi-institutional studies and partnerships with national centers of excellence, which could advance Calidi's research efforts.
Calidi Biotherapeutics (NYSE American: CLDI) will implement a 1-for-10 reverse stock split, effective July 15, 2024. The stock will trade on a split-adjusted basis under the same ticker, CLDI. This decision, approved by shareholders on June 6, 2024, aims to reduce outstanding shares to one-tenth of the pre-split amount.
No fractional shares will be issued; fractional entitlements will be rounded up. The split will adjust equity awards, warrants, and exercise prices accordingly. Shareholders with book-entry or brokerage accounts need not take action, while those with certificate shares will receive instructions from Computershare.
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotech firm focused on antitumor virotherapies, has appointed Dr. George E. Peoples to its Board of Directors, effective July 1, 2024. Dr. Peoples is renowned in cancer immunotherapy, with over 20 years of experience in developing and testing cancer vaccines. He is the Founder and Director of the Cancer Vaccine Development Program and has held significant roles in both military and clinical settings. His expertise is expected to aid Calidi in advancing their cancer immunotherapies into later-stage clinical trials. CEO Allan Camaisa highlighted Dr. Peoples’ pioneering work and extensive experience as key assets for the company’s growth.
FAQ
What is the current stock price of Calidi Biotherapeutics (CLDI)?
What is the market cap of Calidi Biotherapeutics (CLDI)?
